Abstract
Purpose
Sclerotherapy is the mainstay of treatment of macrocystic lymphatic malformation (LM), but the response using traditional sclerosants is much less beneficial in microcystic lesions. Intralesional bleomycin has been reported to be effective in microcystic LM; however, its use is limited by concerns about pulmonary fibrosis. The purpose of this study was to evaluate the safety and efficacy of bleomycin sclerotherapy in microcystic LM.
Methods
The medical records and imaging studies of all patients with microcystic or combined LM who underwent percutaneous image-guided sclerotherapy using bleomycin were retrospectively reviewed. Only patients with pre- and postprocedure imaging were included. Thirty-one patients with a mean age of 13.4 years (range 3 months–31 years) were treated. Response was graded as complete (>90 % size reduction), partial (25–90 %), or minimal/no response (<25 %). Pulmonary function tests (PFT) and chest X-rays were performed before the procedure. PFT were repeated at 6 months and 1 year postprocedure. Annual postprocedure chest X-rays were also performed.
Results
The malformations were located in the head and neck (n = 27) and trunk (n = 4). The number of procedures ranged from 1 to 4 (mean 1.7). Up to 1 U/kg of bleomycin was injected per session, with a maximum of 15 U. The mean follow-up period was 3.2 years (range 1.5–5 years). There was complete response in 38 % (n = 12), partial response in 58 % (n = 18), and no response in 3 % (n = 1). No complications were identified.
Conclusions
Preliminary indicate that sclerotherapy of microcystic LMs using bleomycin is effective and safe.
Similar content being viewed by others
References
Burrows PE, Mitri RK, Alomari A et al (2008) Percutaneous sclerotherapy of lymphatic malformations with doxycycline. Lymphat Res Biol 6:209–216
Chaudry G, Burrows PE, Padua HM, Dillon BJ, Fishman SJ, Alomari AI (2011) Sclerotherapy of abdominal lymphatic malformations with doxycycline. J Vasc Interv Radiol 22:1431–1435
Alomari AI, Karian VE, Lord DJ, Padua HM, Burrows PE (2006) Percutaneous sclerotherapy for lymphatic malformations: a retrospective analysis of patient-evaluated improvement. J Vasc Interv Radiol 17:1639–1648
Sainsbury DC, Kessell G, Fall AJ, Hampton FJ, Guhan A, Muir T (2011) Intralesional bleomycin injection treatment for vascular birthmarks: a 5-year experience at a single United Kingdom unit. Plast Reconstr Surg 127:2031–2044
Fishman SJ (2013) Slow-flow vascular malformations. In: Mulliken JB, Burrows PE, Fishman SJ (eds) Mulliken & Young’s vascular anomalies: hemangiomas and malformations, vol 2. Oxford University Press, Oxford
Burrows PE (2013) Percutaneous treatment of slow-flow vascular malformations. In: Mulliken JB, Burrows PE, Fishman SJ (eds) Mulliken & Young’s vascular anomalies: hemangiomas and malformations, 2nd edn. Oxford University Press, New York, pp 661–710
Yamamoto T, Katayama I (2011) Vascular changes in bleomycin-induced scleroderma. Int J Rheumatol 2011:270938
Ohta H, Chiba S, Ebina M, Furuse M, Nukiwa T (2012) Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol 302:L193–L205
Hashimoto N, Phan SH, Imaizumi K et al (2010) Endothelial–mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 43:161–172
Zhang W, Chen G, Ren JG, Zhao YF (2013) Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations. Br J Pharmacol 170(6):1210–1220
Yura J, Hashimoto T, Tsuruga N, Shibata K (1977) Bleomycin treatment for cystic hygroma in children. Nihon Geka Hokan 46:607–614
Yang Y, Sun M, Ma Q et al (2011) Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surg 53:150–155
Perkins JA, Manning SC, Tempero RM et al (2010) Lymphatic malformations: review of current treatment. Otolaryngol Head Neck Surg 142:795–803, 803.e1
O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91–96
Comis RL (1992) Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol 19:64–70
Blum RH, Carter SK, Agre K (1973) A clinical review of bleomycin—a new antineoplastic agent. Cancer 31:903–914
Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO (2004) Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int 19:766–773
Ionescu G, Mabeta P, Dippenaar N, Muir T, Fourie P, Shelver G (2008) Bleomycin plasma spill-over levels in paediatric patients undergoing intralesional injection for the treatment of haemangiomas. S Afr Med J 98:539–540
Sleijfer S (2001) Bleomycin-induced pneumonitis. Chest 120:617–624
Atwa K, Abuhasna S, Shihab Z, Hashaykeh N, Hasan R (2010) Acute pulmonary toxicity following intralesional administration of bleomycin for a lymphovenous malformation. Pediatr Pulmonol 45:192–196
Mertens AC, Yasui Y, Liu Y et al (2002) Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 95:2431–2441
Conflict of interest
None of the authors have declared a conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chaudry, G., Guevara, C.J., Rialon, K.L. et al. Safety and Efficacy of Bleomycin Sclerotherapy for Microcystic Lymphatic Malformation. Cardiovasc Intervent Radiol 37, 1476–1481 (2014). https://doi.org/10.1007/s00270-014-0932-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-014-0932-z